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Background: Denmark is one of the countries where Human papillomavirus (HPV)-vaccination at present
includes only girls. However, the burden of HPV-related cancer in men is increasing, which would argue
for gender-neutral vaccination. The aim of this study was to examine the burden of HPV-caused cancers
in women and men, and to evaluate the potential of HPV-vaccination in cancer control.
Methods: Data were retrieved from the literature on population prevalence of high risk (HR) HPV, on HR
HPV-prevalence and genotypes in HPV-related cancers, and on number of cytology samples in cervical
screening. Data on annual biopsies and conisations were retrieved from the Danish National Health
Service Register and the Danish National Patient Register. Incidences of HPV-related cancers in
Denmark were extracted from NORDCAN. Number of HPV-caused cancers was calculated from number
of HPV-related cancers and the proportion known to be caused by high-risk (HR) HPV.
Results: In cross-sectional surveys in Denmark, one fifth of women and almost one third of men were
found to be positive for HR HPV. Per year, 548 HPV-caused cancer cases were diagnosed in women
and 234 in men, and twice as many cancers in women as in men were preventable with HPV vaccination.
However, including screening prevented cervical cancers, the burden of cancers caused by HPV-infection
would be 1300–2000 in women as compared to 234 in men.
Conclusion: Taking screening prevented cervical cancers into account, the cancer control potential of
HPV-vaccination is considerably higher in women than in men. HPV-vaccination could reduce the burden
of screening on women and on health care resources.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
High-risk (HR) human papillomavirus (HPV) is involved in the
pathogenesis of ano-genital and some head and neck cancers,
and low risk (LR) HPV 6 and 11 in benign ano-genital conditions
[1].
In September 2006 and 2007, respectively, the quadrivalent
HPV-vaccine Gardasil (Merck) and the two-valent HPV-vaccine
Cervarix (GSK) obtained license in the European Union for use
in both men and women from the age of nine years. Both vaccines
are recombinant and contain proteins from HPV 16 and 18, which
cause 70% of cervical cancers [2]. In addition, Gardasil contains
proteins from HPV 6 and 11. Vaccine efficacy studies have shown
that Gardasil and Cervarix are both highly protective againstHPV-vaccine-type infection and cervical intraepithelial neoplasia
(CIN) in persons HPV-näive at the time of vaccination [3,4]. Futher-
more, Gardasil protects against condyloma and perineal intraep-
ithelial neoplasia (PIN) in men, though the evidence for the latter
is based on small numbers [5]. In June 2015, the nine-valent
HPV-vaccine Gardasil9 obtained license in the European Union.
This vaccine protects against the HR HPV 16, 18, 31, 33, 45, 52,
and 58 besides HPV 6 and 11. The seven HR HPV-types cause
90% of cervical cancer [2], and Gardasil9 is highly protective
against HPV-vaccine type lesions in persons HPV-näive at the time
of vaccination [6].
National HPV-vaccination programs have been implemented in
at least 64 countries [7], including all Nordic countries. In
Denmark, HPV-vaccination became part of the child vaccination
program for 12 year-old girls in 2009. Before and after there have
been temporary catch-up programs for girls and women up to
the age of 26 years [8]. In most countries, HPV-vaccination is rec-
ommended for girls only, and cost-effectiveness analyses generally
conclude that HPV-vaccination of boys is not cost-effective [9].
However some countries, including Australia, the US, parts of
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vaccination [10–14].
In Denmark, HPV-vaccination is at present offered to girls. But
vaccination of boys has been debated, and the argument for vacci-
nation has been supported by the recent observation of an increase
in the burden of HPV-related cancers in men [15,16]. The aim of
the present paper is to estimate the burden of cancers in Denmark
in women and men caused by HPV-infection and to evaluate the
impact of HPV-vaccination in cancer control.2. Material and methods
For each cancer site, we tabulated number of HPV-related cases,
defined as all cases with a given site-specific ICD-10 code.
Furthermore, we calculated number of HPV-caused cases, defined
as proportion of HPV-related cancers assumed to be caused by
HPV-infection. We also calculated the number of cancers pre-
ventable by the two-/ quadrivalent and the nine-valent HPV-
vaccines, respectively.
Cancers related to HPV-infection include cancers of the cervix,
vulva, vagina, penis, anus and some head and neck cancers
[1,17]. From NORDCAN [18], we retrieved data on incidence rate,
number of incident cases, and number of deaths from these cancers
in 2010–2014. For head and neck cancer, we focused on oropha-
ryngeal cancer (OPC) because this is the subgroup most closely
associated with HPV [1,15]. The following International Classifica-
tion of Diseases (ICD)-10 codes were used: oropharynx (C01,
C05.1-9, C09, C10.0, C10.2-9) and cervix (C53). Data on penile can-
cer (C60), vulvar cancer (C51), vaginal cancer (C52) and anal cancer
(C21) were not specified in the publicly available version of NORD-
CAN, and these data were therefore retrieved from the web-page of
the Danish Cancer Society [19].
Data on HPV-prevalence and genotype distribution in men [20]
and women [21] as well as in the selected cancers were retrieved
from the literature [2,16,17,22–24]. When available, Danish stud-
ies were used, otherwise European. Data on HPV-vaccination cov-
erage was retrieved from Statens Serum Institute (SSI) [25]. Data
on number of cervical cytology samples were retrieved from the
annual report of the Danish Quality Database for Cervical Cancer
Screening (DKLS) [26]. From the Danish National Health Service
Register (NHSR) [27] and the Danish National Patient Register
(NPR) [28] we obtained combined data from private gynaecologists
and hospitals on number of cervical biopsies and conisations. NHSR
holds information on service provided by private gynaecologists,
and NPR holds information about in- and outpatient contacts to
hospitals.
In order to assess the total burden of HPV caused cancer in
women, we estimated the number of cervical cancer cases pre-
vented by screening. We used three approaches. First, a previous
estimate for Denmark found that one cervical cancer case was pre-
vented for every 6–8 conisations [29]. Second, a study from New
Zealand showed that 31.3% of CIN3 left untreated progressed to
cervical cancer within 30 years [30]. Finally, it has been estimated
that cervical cancer incidence in Denmark in the absence of screen-
ing would have been five times higher in 2006–2010 than
observed; comparable with the highest incidence currently
observed in low-income countries [31].3. Results
3.1. HPV prevalence in the population
Two studies both used Hybrid capture 2 (HC2) and polymerase
chain reaction (PCR) to estimate the HPV-prevalence and genotype
distribution in the Danish population [20,21]. When testing 2436men aged 18–65 years, 30% were positive for HR HPV, 5.8% for
HPV-16, 4% for HPV-18, 3% for HPV-31, 1.5% for HPV-33, 1.5% for
HPV-45, 3.4% for HPV-52 and 0.8% for HPV-58. In 40,382 women
aged 14–95 years, the HR HPV prevalence was 20.5%, 5.4% were
positive for HPV-16, 2.4% for HPV-18, 3.8% for HPV-31, 1.7% for
HPV-33, 1.9% for HPV-45, 3.9% for HPV-52 and 1.2% for HPV-58.
3.2. Burden of HPV related cancers in men and women
On average, 376 women annually were diagnosed with cervical
cancer in 2010–2014 (Table 1). For cancers in the vulva and vagina,
there were 108 and 17 new cases per year, respectively. For anal
cancer, 97 women were diagnosed per year, and for OPC 102
women. In men, the annual number of new cases was 61, 41 and
282 for penile cancer, anal cancer and OPC, respectively (Table 1).
In total, 700 women and 384 men per year were diagnosed with an
HPV-related cancer. This translates into age-standardized inci-
dence rates (World standard population) of 15.4 per 100,000
women and 5.5 per 100,000 men according to a newly published
ICO report [32].
3.3. Burden of cancers caused by HPV in men and women
It is widely accepted that persistent HR HPV infection is a nec-
essary condition for development of cervical cancer. Walboomers
et al. concluded that all cervical cancers are caused by HPV [17].
A study found an HPV-prevalence of 96% in invasive cervical cancer
in Danish women [24]. This included two cases of LR-HPV out of
261 cervical cancers. Although the deficit may be due to technical
artefacts, there is probably also a minor group of truly negative cer-
vical cancers. HR HPV is estimated to cause between 32% and 84%
of the other HPV-related cancers in men and women (Table 1).
The annual number of cancers in Danish women caused by HR
HPV thus became 361, 38 and 13 for cervical, vulvar and vaginal
cancer, respectively, 81 for anal cancer, and 55 for OPC (Table 1).
The annual number of cancers in Danish men caused by HPV
became 20, 34 and 180 for penile cancer, anal cancer and OPC,
respectively (Table 1). In total, 548 women and 234 men per year
were diagnosed with a cancer caused by HPV (Fig. 1).
3.4. Burden of preventable cancers caused by HPV in men and women
HPV16 is the most common genotype in HPV-caused cancers in
both sexes (Table 1). HPV18 is the second or third most common in
anal-, vulvar-, vaginal- and cervical cancer, but accounts for a very
small part in penile cancer and OPC. In total, 401 cancers in women
and 197 cancers in men were caused by HPV 16 and 18, two HPV
types covered by the two-/quadrivalent vaccines. Approximately
472 cancers in women and 213 cancers in men are caused by the
seven HR HPV covered by the nine-valent vaccine (Table 1).
3.5. Cervical screening in Denmark
In 1962, a pilot-screening programwas undertaken in Denmark.
In 1967, three regional organized programs began, and opportunis-
tic screening started in 1969. National guidelines first came in
1986 recommending screening of women aged 23–59 years every
third year. In 2007 this was changed to screening every third year
for women aged 23–49 years and every fifth year for women 50–
65 years of age. The present guidelines were issued in 2012, adding
an HPV-DNA checkout test for women aged 60–64 [8]. Since the
introduction of screening, the incidence of cervical cancer has
decreased from 44.4 per 100,000 (Nordic standard population) in
1966 to 14.5 per 100,000 in 2014. Mortality decreased from 16
per 100,000 in 1966 to 3.1 per 100,000 in 2014 (Fig. 2).
Table 1
HPV-related cancers in Denmark, 2010–2014.
HPV related
cancer type
Number of new
cases per year
(2010–2014)
Proportion of
cancers caused by
HR HPV (%)
HR HPV genotypes
(% of prevalence)c
HR HPV 16
and 18
prevalence
(%)
HR HPV 16, 18 31, 33,
45, 52 and 58
prevalence (%)
Estimated cases caused by
All
HR
HPV
HR HPV
16 and
18
HR HPV 16, 18,
31, 33, 45, 52,
and 58
Women
Cervical 376 96 [20] 16 (66) 18 (7), 31 (3), 33 (6),
45 (4), 52 (2), 58 (1) [2]a
74 [20] 90 [20] 361 267 325
Vulvar 108 35 [18] 16 (32.2), 18 (4.4), 31 (0.6),
33 (4.5), 45 (1), 52 (0.7), 58
(0.0) [18]
37 43 38 14 16
Vaginal 17 77 [18] 16 (57.4), 18 (7.1), 31 (0.0),
33 (2.9), 45 (1.5), 52 (1.5), 58
(0.0) [18]
65 71 13 8 9
Anal 97 84 [18]b 16 (73.4), 18 (5.2), 31 (1.9),
33 (4.8), 45 (0.5), 52 (0.0), 58
(0.0) [18]
79 86 81 64 70
Oropharyngeal 102 54 [12] 16 (86), 18 (0.9), 31 (0.4) 33
(6.3), 45 (0.2), 52 (-), 58 (0.2)
[12]
87 94 55 48 52
Total women 700 548 401 472
Men
Penile 61 32 [19] 16 (68.7), 18 (1.5), 33 (2.9),
31 (0.8), 45 (2.7), 52 (1.5), 58
(1.3) [19]d
70 77 20 14 15
Anal 41 84 [18]b 16 (73.4), 18 (5.2), 31 (1.9),
33 (4.8), 45 (0.5), 52 (0.0), 58
(0.0) [18]
79 86 34 27 29
Oropharyngeal 282 64 [12] 16 (86), 18 (0.9), 31 (0.4), 33
(6), 45 (0.3), 52 (), 58 (0.2)
[12]
87 94 180 156 169
Total men 384 234 197 213
a Genotype distribution from other Ref. [2] because of missing separate data on all genotypes in [20].
b Proportion not separate for men and women.
c Genotype distribution not separate for men and women for anal and OPC.
d Genotypes taken from single and multiple, Table 3 [19].
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Fig. 1. Cancers cases caused by HPV in Denmark 2010–2014.
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Of these 41,003 were abnormal. In total, 24,553 biopsies from the
cervical portio and 6119 conisations were performed. In 2010–
2014, an annual number of 376 women were diagnosed with cer-
vical cancer, and 99 died from the disease (Fig. 3).
The total burden of HPV-caused cancer in women, including
screening prevented cervical cancers resulted in the following esti-
mates based on three earlier described approaches. First, with6119 conisations per year, we would expect 765–1020 cervical
cancer cases to have been prevented by screening; added to the
present 376 cases it gives a total of 1141–1396 cases. Second, with
a present number of 4399 CIN3 cases per year in Denmark [15],
this would give 1377 cervical cancer cases prevented by screening.
Added to the 376 present cases this would give 1753 cases. Third,
without screening a total of 1846 women (NORDCAN incidence
2006-2010x5) would then have been diagnosed with cervical
cancer.
Without screening, every year somewhere between 1100 and
1800 Danish women would have been diagnosed with cervical
cancer. When accounting for an HPV prevalence of 96% in cervical
cancer [24], and adding the 187 cases of other cancer types caused
by HPV in women (Table 1), every year approximately 1300–2000
HPV-caused cancer cases would occur in women in total compared
to 234 cases in men.
3.6. HPV-vaccination coverage in Denmark
In Denmark, HPV-vaccination coverage has been quite high
until recently. To begin with, coverage for the first dose was around
80% and increased to over 90% for girls born in 1998–2000. The
corresponding coverage for full vaccination was close to 80%. How-
ever, girls born in 2004, only 45% received the first dose, and – as of
today - as few as 17% were fully vaccinated (Fig. 4) [25].
4. Discussion
Our study showed that although the prevalence of
HPV-infection was high in both men and women in Denmark,
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Fig. 2. Age-standardized (Nordic standard population) incidence and mortality rates for cervical cancer with historical marks for the screening program. Source: Data
retrieved from NORDCAN [18].
Cervical
cancer1 376
Conisation2 6119
Biopsy2 24,553
Abnormal cytology sample3 41,003
Cytology sample3 386,662
Death1 99
Fig. 3. Activities in the cervical screening program in Denmark. Source: 1NORDCAN,
2NHSR and NPR, 3DKLS annual report 2015.
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higher in women than in men; 548 cases in women and 234 cases
in men, and twice as many cancers in women as in men were pre-
ventable with HPV-vaccination. Furthermore, the incidence of cer-
vical cancer has declined significantly since the 1960s due to a
well-functioning screening program. We estimated that the actual
number of cervical cancers without screening would have been 3–5
times higher than it is today. Including the screening prevented
cases, the burden of cancers caused by HPV-infection would be
1300–2000 cases in women as compared to 234 cases in men.
Cervical screening has existed for so long that we tend to take it
for granted. But cervical screening is a major burden both for
women and for the health care system. In Denmark, with approx-
imately 1.5 million women in screening age [33], every year almost
350,000 women have a screening sample taken; 40,000 have to
come back for further examinations; and 25,000 have to visit agynecologist to have a cervical biopsy taken. All of these numbers
represent women who have to take time off work or other activi-
ties to have a test performed and to wait for the answer. Annually,
more than 6000 women - equal to 20% of a birth cohort - have a
conization performed. Although conization with large loop exci-
sion of the transformations zone (LLETZ) is a minor surgical proce-
dure, it can cause bleeding and a risk of infection, and a Danish
study found almost a doubling of the risk of preterm birth after
LLETZ [34], an observation supported by other studies [35,36].
It is therefore highly desirable to lessen the burden of screening
in the control of cervical cancer by primary prevention in terms of
vaccination. This is, however, not straightforward due to the differ-
ences in progression rates across HR HPV-types. Although Gar-
dasil prevents 70% of cervical cancer, it prevents only 43% of
CIN2+, and 17% of abnormal cytology [37], and Cervarix prevents
70% of CIN2+ [4]. Gardasil9 is expected to prevent 70% of CIN2+
(43% as for Gardasil + 39.6% [6] of the remaining 67%). In Den-
mark, women with CIN2 in childbearing age are recommended
for follow-up with colposcopy and biopsy after 6 months. Women
with CIN3 are recommended for immediate conization and for con-
trol colposcopy after 6 months [38]. According to the outcome of
the randomized controlled trials on HPV-vaccines in women vacci-
nated as HPV-naïve, the Danish follow-up and treatment burden
will thus be reduced by 43% with Gardasil, 70% with Cervarix
and 70% with Gardasil9 vaccines. With new assays and algo-
rithms, the residual pool of slow progressing lesions can hopefully
be controlled with less intensive screening; this is in particular
expected if only 10% of cervical cancers remain to be prevented
by screening.
Our data presented the current situation in Denmark. However,
the pattern of higher burden in women seems to be similar across
Northern European. Based on the European ICO report [39] the age-
standardized incidence rates (World standard population) for HPV-
related cancer in Sweden is 11.1 per 100,000 women and 3.9 per
Fig. 4. HPV-vaccination coverage in Denmark. Source: Data retrieved from Statens Serum Institute [25].
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100,000 men and in England 11.1 per 100,000 women and 5 per
100,000 men. Recent Danish age-period-cohort modeling of inci-
dence data indicated an increase in the HPV-related cancer burden
of men and a decrease in the burden of women [15]. Based on these
trends, it was argued that ‘‘if the incidence of HPV-associated cer-
vical cancer . . . continues to decrease and that of oropharyngeal
cancer continues to increase in men” then the cancer burden attri-
butable to HPV ‘‘in men will surpass that of women in the near
future” [11 p 558]. In eastern Denmark, the age-standardized inci-
dence for OPC increased from 4.0 per 100,000 in 2011 to 4.5 in
2014, and the number of OPC cases was predicted to exceed the
number of cervical cancer cases in 2016 [16]. However, when the
screening prevented cervical cancer cases are taken into account,
the vaccines can prevent 6–8 times more cancers in women than
in men.
There is thus from a public health point of viewno doubt that the
cancer prevention potential of HPV-vaccination is considerably lar-
ger for women than for men. So, how are women best protected?
Here both vaccination coverage and herd immunity have to be
taken into account. A meta-analysis of modeling studies found that
with a vaccination coverage of girls of at least 80%, both women and
men would be well protected against infection with the vaccine
HPV-types [40]. However, if the coverage of vaccination in girls
was 60% or below, the relative reduction in HPV-prevalence was
considerably improved if both girls and boys were vaccinated. This
was in particular true for HPV-16. Another argument for male vac-
cination is to protect men who have sex with men (MSM), as they
are not protected by herd immunity of female vaccination.
In Denmark, vaccination coverage among girls born 1998–2000
was almost 80%. Vaccination of boys would thus have contributed
very limited to the reduction of HPV-prevalence in both girls and
boys. However, the HPV-vaccination coverage has dropped dra-
matically in Denmark in the past couple of years due to public con-
cern about possible side effects. A Swedish modeling study found
that gender-neutral HPV-vaccination would offer good protection
for both men and women, even in situations of impaired coverage
[41]. From a public health point of view this would argue for HPV-
vaccination of boys. However, the present situation, with only 17%
of a birth cohort of girls being fully vaccinated, could be compen-
sated only by a vaccination program in boys with a high atten-
dance rate. If women were willing to comply with vaccination,
extra money might – from a population point of view - be better
spent on Gardasil9 vaccination of girls than on Gardasil/Cervarix vaccination of boys, as Gardasil9 vaccination would
protect both women and men, and reduce the need for screening.
Our study has limitations. The reported prevalence of HR HPV
and genotype distribution in different cancers vary between
countries and studies probably due to variation in underlying
risk, sexual behavior, and method of analysis. Whenever
possible we used Danish data and otherwise European data, but
data were collected from several studies, and the combined
numbers were subject to some degree of uncertainty. The HPV-
prevalences we used were largely in accordance with those used
in other studies [32,42,43], with some exceptions. For example,
the prevalence of HPV16 in vulvar cancer varied from 32.2% in
our reference to 68% in another [42], and in the ICO report [32]
the HPV prevalence in vaginal cancer was somewhat higher
88.9% compared to our reference 77%. This may lead to an under-
estimation of preventable cancer cases in women. Likewise the
HPV prevalence in penile cancer may have been underestimated
in our analysis. In our reference 32% of penile cancers were HPV-
positive compared to 51% in another [43]. When calculating cancer
cases preventable by vaccination we added the relative contribu-
tions across genotypes without accounting for multiple infections.
This could result in overestimation. The preventive effect of the
nine-valent vaccine on cervical cancer may be underestimated
because HPV-52 was not included in the estimate. In our analysis
we used an HPV-prevalence of 96% from a Danish study, allowing
for a small proportion of invasive cervical cancers to be truly HPV-
negative [24]. NORDCAN data on incidence of HPV-related cancer
types was used. For Denmark, this database builds on the Danish
Cancer Register known to have high accuracy. In this study, we
focus only on cancer outcomes. This is a limitation when assessing
the potential of HPV-vaccination. However, according to the Dan-
ish Health Authorities, a criteria for introducing new vaccines into
the child vaccination program is that the illness prevented by the
vaccine is serious enough to justify risk of possible side-effects
[44]. Protection against benign conditions, such as condyloma, is
therefore not included in this study.
In summary, the cancer prevention potential of HPV-
vaccination cannot be estimated only from the present number
of cancers. For women, we see only the tip of the iceberg because
screening today prevents the majority of the cervical cancer cases
that would otherwise have occurred. But screening is a serious bur-
den both on women and on the health care system, and HPV-
vaccination will decrease the need for screening, especially if 90%
of cervical cancers were prevented by vaccination. The potential
5944 M. Skorstengaard et al. / Vaccine 35 (2017) 5939–5945impact of HPV-vaccination on the future cancer burden is thus
even more beneficial when the hidden iceberg of cervical cancers
is taken into account.
5. Conclusion
At present, cancers caused by HPV-infections were twice as
common in women as in men in Denmark, and twice as many can-
cer cases were preventable with HPV-vaccination. Furthermore,
there was a hidden burden of HPV-caused cancers in women
because the present level of cervical cancer results from 50 years
of screening and treatment of precancerous lesions. Indeed, when
cervical cancers prevented by screening were included in the esti-
mate, the burden of HPV-caused cancers was 6–8 times higher in
women than in men. It is therefore highly desirable to lessen the
burden of screening in the control of cervical cancer by primary
prevention in terms of vaccination. High vaccination coverage of
girls would offer effective protection against HPV-infections in
both women and men. Somewhat lower vaccination coverage of
girls could be compensated for by vaccination of boys. Unfortu-
nately, Denmark at present has such a low vaccination coverage
of girls that compensation from vaccination of boys would be
achieved only if the coverage in boys would be high. First of all,
the present low vaccination coverage of girls in Denmark has neg-
ative consequences for both women and men, and concerted
efforts should be taken to increase this coverage.
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